Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

F520 combined with chemotherapy

Preclinical

SShandong New Time Pharmaceutical Co., LTD

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Cancer of Unknown Primary SiteRecruiting

Cancer of Unknown Primary SitePreclinical

Recruiting

Timeline

Expected Milestones

Q2 2028

PreclinicalRecruiting

Cancer of Unknown Primary Site

NCT07761429

Clinical

Trials by Indication[1]

Cancer of Unknown Primary Site1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study Evaluating the Safety and Efficacy of F520 Combined With Paclitaxel Plus Carboplatin as First-line Treatment for Cancer of Unknown Primary

Recruiting·SShandong New Time Pharmaceutical Co., LTD·Preclinical·NCT07761429·402 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for F520 combined with chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for F520 combined with chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Shandong New Time Pharmaceutical Co., LTD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: SShandong New Time Pharmaceutical Co., LTD

Related News